Population
Hemodialysis (HD) patients with systolic hypertension
Design
Review
Authors
Loading...
Supports ACE inhibitor or beta-blocker use and daily dialysis in hemodialysis hypertension; leaves open confirmation by randomized trials.
Systolic hypertension is a major cardiovascular risk factor in hemodialysis patients and should be managed with nonpharmacologic measures followed by ACE inhibitors or beta-blockers.
Rajiv Agarwal (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: